Angoron

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Angoron

Quick Facts

Property Description
Active Ingredient Amiodarone Hydrochloride
Form Tablets; Injectable Solution
Pharmacological Class Class III Antiarrhythmic Agent
General Purpose Stabilization of heart rhythm
Origin Synthetic organic compound

What is Angoron? Definition and Pharmacological Class

Angoron is a specialized, prescription-only medication that contains the active ingredient Amiodarone Hydrochloride and is fundamentally used to stabilize the heart's electrical system. It is formally classified as a Class III Antiarrhythmic agent within the Vaughan Williams' system, which recognizes its core ability to prolong the action potential duration in cardiac tissue. This classification highlights the drug's potent capability to regulate electrical impulses in the heart. Amiodarone Hydrochloride is a synthetic chemical entity, specifically a Benzofuran derivative, that possesses a distinct, complex chemical structure.


Composition, Origin, and Available Forms

The medication is a single active ingredient product consisting solely of Amiodarone Hydrochloride, which is chemically unique as an iodine-rich compound. The medication's availability addresses both acute and chronic needs, distinguishing its utility: it is supplied as oral tablets for long-term maintenance therapy and as an injectable solution for immediate, rapid delivery via the intravenous route.


General Therapeutic Purpose

The overarching purpose of this Antiarrhythmic agent is to control and prevent serious, recurring electrical disturbances known as cardiac dysrhythmias. The medication is effective in suppressing and preventing both ventricular and supraventricular arrhythmias. This means the medication helps the heart maintain a safe and regular rhythm by counteracting chaotic or excessively rapid electrical signals. By prolonging the cell recovery time (the refractory period), Angoron ensures that the heart's electrical system remains stable and functional.

What side effects are possible with Angoron?

Possible Side Effects and Safety Information

The official safety profile of Angoron (Amiodarone Hydrochloride) is characterized by the potential for complex, multi-organ system toxicity, requiring specific safety monitoring as documented in regulatory sources.

Adverse Reaction Classification

Side effects are formally classified by frequency and by the system-organ classes they affect:

Frequency Classification Examples of Officially Listed Adverse Reactions
Very Common (1/10) Corneal microdeposits, isolated hepatic enzyme elevation, gastrointestinal disturbances.
Common (1/100 to < 1/10) Hypo- or Hyperthyroidism, photosensitivity, pulmonary toxicity (pneumonitis), peripheral neuropathy.
Uncommon Onset or worsening of arrhythmia (proarrhythmia), conduction disturbances.

Serious Adverse Reactions and Systemic Risk

Regulatory documents highlight the risk of serious adverse reactions, including potentially fatal Pulmonary Toxicity (e.g., fibrosis), severe Hepatotoxicity (including acute liver failure), and life-threatening Proarrhythmia (such as Torsade de Pointes). Cases of Optic Neuropathy/Neuritis, which may result in permanent blindness, have also been reported in the regulatory safety information.

Exposure-related patterns specify that effects like gastrointestinal upset are often observed at treatment initiation, while severe toxicities (e.g., chronic liver disease) are typically associated with long-term exposure. Safety limitations include contraindications in patients with severe sinus bradycardia or specific degrees of AV block, unless a functioning pacemaker is present. Older adults may be more susceptible to marked bradycardia. The official profile underscores the necessity for regular monitoring of liver, thyroid, and lung function.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Angoron (Amiodarone Hydrochloride) overdose focuses on severe, documented effects on the cardiovascular system and the immediate need for emergency intervention.

Documented Overdose Manifestations Overdose is primarily characterized by severe cardiac effects, including marked Bradycardia (profound slowing of the heart rate), Severe Hypotension (critically low blood pressure), and Atrioventricular (AV) Block. Gastrointestinal distress, such as nausea, may also be present.

Life-Threatening Outcomes and Required Actions Regulatory documents identify the potential for life-threatening consequences, such as Cardiogenic Shock, Asystole (cardiac arrest), and acute Hepatocellular Necrosis (acute liver injury), particularly following high-concentration exposure. Due to the high risk of severe outcomes, individuals experiencing symptoms of overdose must seek immediate medical attention. If the medication is being administered intravenously, regulatory guidance dictates that the infusion rate must be slowed or discontinued immediately upon observing signs of severe hypotension or bradycardia.

Management and Limitations The official information states that no specific antidote is known for Angoron overdose, and the drug is not removable by dialysis. Management is strictly limited to symptomatic and supportive treatment. This may include procedural interventions such as temporary cardiac pacing for severe bradycardia or the use of vasopressor agents and volume expansion to treat refractory hypotension. Continuous electrocardiographic monitoring is required due to the risk of severe, sustained cardiotoxicity.

Therapeutic Uses of Angoron

What Angoron Treats: Main Uses and Benefits

Angoron, which contains amiodarone, is commonly used to help with symptoms related to severe cardiac rhythm disturbances. Its application is relevant for managing conditions associated with acute or disruptive episodes and symptoms that create noticeable physiological strain. The medicine is applied in addressing life-threatening abnormal heart rhythms in adults.

The main therapeutic domain for Angoron is the management of severe ventricular arrhythmias. This includes conditions such as recurrent ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT). It is also considered relevant for other symptom clusters related to heart rhythm, including specific supraventricular tachycardias (SVTs) and atrial fibrillation. The agent is often used in scenarios where additional symptomatic support is needed.

The application of this agent contributes to improved comfort, often used in clinical settings that involve acute or unstable symptom patterns. This use helps to ease the overall symptom burden, and may assist patients with maintaining functional stability during episodes where symptoms become more noticeable.


Quick Fact: Relief for Symptoms related to heightened physiological activity.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Angoron — Official Regulatory Information

The eligibility for Angoron (Amiodarone Hydrochloride) is defined by official regulatory bodies, focusing on patient status, coexisting conditions, and reproductive state. This framework determines who may use the medicine and who must be excluded.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults with documented life-threatening ventricular arrhythmias, typically when other antiarrhythmic agents have failed or were not tolerated.
Populations for whom use is contraindicated Patients with known hypersensitivity to iodine or amiodarone, those experiencing Cardiogenic Shock, or individuals with marked Sinus Bradycardia.
Contraindicated for patients with Second- or Third-Degree Atrioventricular (AV) Block or Sick Sinus Syndrome unless a functioning pacemaker is present.
Age-related eligibility rules Pediatric Population: Safety and efficacy have not been established in this population.
Pregnancy and lactation status Pregnancy: Use is restricted; only if the potential benefit justifies the risk to the fetus. Lactation: Mothers should be advised to discontinue breastfeeding.
Eligibility-related restrictions Patients with severe Left Ventricular Dysfunction require close clinical monitoring during treatment.

Eligibility Classifications (High-Level)

Official regulatory documents categorize these rules as Contraindicated, Use Not Established, or Use with Caution/Monitoring Required, establishing the mandatory boundaries for the drug's use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Angoron (Amiodarone Hydrochloride) has documented interaction patterns that are classified by regulatory authorities as pharmacokinetic, pharmacodynamic, or involving mandated co-administration restrictions. The official interaction profile defines several contraindicated combinations, including other Class Ia and Class III antiarrhythmic agents, and specific non-antiarrhythmic QT-prolonging medicines. Co-administration with these is formally prohibited due to the heightened risk of adverse cardiac events.

Pharmacokinetic Interactions

Amiodarone is officially documented as a potent inhibitor of several metabolic enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A, as well as the P-glycoprotein (P-gp) transporter. This broad inhibition results in increased plasma concentrations of many co-administered medicinal products. For instance, the official label notes that this necessitates restrictions for Warfarin, Digoxin, and Simvastatin. The required daily dose of Simvastatin must not exceed 10 mg when used concurrently.

Substance and Timing Constraints

The co-administration of oral Angoron with Grapefruit juice is officially restricted as it significantly increases Amiodarone's plasma exposure. Furthermore, a high-fat meal is documented to dramatically increase the drug's oral absorption. Due to Angoron’s unusually long regulatory half-life, the potential for clinically significant drug interactions is documented to persist for several weeks to months following its final dose.

Mechanism of Action

Multi-Channel Electrical Modulation and Action Potential Prolongation

Angoron (Amiodarone) initiates its electrophysiological activity primarily by interfering with the flow of ions through voltage-gated Potassium, Sodium, and Calcium channels in heart muscle cells. This comprehensive multi-channel blockade significantly prolongs the cardiac action potential duration and, crucially, increases the Effective Refractory Period (ERP). This mechanism is key to reducing the potential for disorganized electrical activity by ensuring that tissue remains unresponsive to chaotic signals, thereby resulting in the maintenance of an organized electrical pattern.


Autonomic and Vascular Pathway Modulation

Beyond its direct effects on ion channels, Angoron acts as a non-competitive antagonist on alpha- and beta-adrenergic receptors. This systemic action modulates the sympathetic nervous system input to the heart, leading to a functional slowing of the heart rate and attenuation of contractility. Furthermore, alpha-receptor blockade causes peripheral vasodilation. These actions collectively reduce cardiac mechanical strain and energy requirement, contributing to the overall electrophysiological changes.


Mechanistic Constraints

The drug’s high lipophilicity means that full saturation of myocardial tissue and maximal mechanistic effect is achieved only after a long period of gradual cellular accumulation. Moreover, the essential mechanism of prolonging the repolarization phase (QT interval) carries an inherent constraint, as this electrical change can—in specific contexts—create conditions for potential electrical heterogeneity and instability (e.g., Torsades de Pointes).

Dosage and Administration Information

Angoron (Amiodarone Hydrochloride) is administered through a strictly defined protocol that involves two primary routes. The oral route is used for long-term therapy via tablets, while the intravenous (IV) infusion is reserved for acute, immediate management in controlled settings.

Therapy follows a phased dosing regimen. Oral treatment begins with a high-dose loading period, typically ranging from 800 mg to 1600 mg daily, which is often divided into multiple administrations for better tolerability. This loading phase continues for one to three weeks until the dose is progressively lowered to the typical maintenance dose of 400 mg once daily. For IV administration, a total dose of approximately 1000 mg is delivered over the initial 24 hours using a complex, multi-step infusion schedule.

Specific instructions govern the proper administration of the medicine. Oral tablets may be taken with or without food, but consistent timing concerning meals is advised. The injectable solution requires specific preparation, mandating dilution only in Dextrose 5% in Water (D5W), and must be delivered using a volumetric infusion pump. Furthermore, concentrations exceeding 2 mg/mL must be administered via a central venous catheter. Initiation of Angoron therapy is generally required to occur under specialist supervision. If an oral dose is missed, instructions specify skipping the dose and returning to the regular schedule without taking a double amount.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Angoron


Evidence for Use in Managing Acute Heart Events

Research examined Angoron in studies focusing on conditions associated with acute or disruptive episodes. These studies typically looked at patients who had recently experienced an acute heart event. The research examined whether Angoron administration during these periods was associated with patterns in outcomes describing episodic or acute changes. The types of studies conducted included randomized controlled trials applied in research contexts involving fluctuating or unstable symptoms.

The findings describe patterns observed in the studies regarding outcomes related to systemic or functional imbalance in the heart. Research highlights changes measured during the study period, such as markers of physiological strain or stress, and how outcomes monitoring physiological strain or stress were measured in the observed populations. For many of these studies, the focus was on short-term symptom changes and initial hospital outcomes. The data show patterns related to an acute phase of the condition.

How Different Doses Were Studied

Within the research for acute heart events, studies explored different amounts, or doses, of Angoron. This was done to understand how the amount of medicine administered related to the outcomes monitored in the studies. Researchers monitored how various doses related to the physical and functional observations recorded. Evidence quality varies across studies comparing different doses, and the results apply only to the populations studied and the specific time intervals over which they were monitored.


Evidence for Use in Supporting Chronic Heart Function

Angoron was studied for its potential use in patients managing conditions marked by functional limitations related to long-term heart issues. This research was applied in studies examining patient-reported experiences as well as physician-measured outcomes reflecting daily functioning or activity level over longer periods, often several months or more. The trials were designed to observe how outcomes related to physical discomfort and daily functioning evolved during the defined study intervals.

Studies observed Angoron was associated with outcomes related to systemic or functional imbalance in some study participants. The trials monitored patient-reported outcomes describing perceived discomfort and changes in physiological function using standard clinical tests. The evidence contributes to the broader evidence landscape by showing patterns of change in conditions where symptoms may vary in intensity. However, follow-up durations were limited in many of these studies, meaning less is known about the effects over many years.

Frequently Asked Questions (FAQ)

Common questions about Angoron (FAQ)

Q: Can Angoron be used for conditions other than the main ones listed?

A: Official regulatory documents define the approved use as the treatment and prevention of certain types of serious, life-threatening heart rhythm problems. While the medicine is sometimes used for other types of heart rhythm issues, it is important to understand the risks of using the medicine for any condition not explicitly listed in the official indications.

Q: Does Angoron cause weight gain?

A: Official safety information lists both weight loss and weight gain as possible side effects, which may be associated with the drug's effects on the thyroid gland. Patients experiencing unusual changes in weight are encouraged to discuss these with a healthcare professional.

Q: What are the most common side effects of Angoron?

A: According to official regulatory documents, the most frequently reported side effects include gastrointestinal issues such as nausea, vomiting, constipation, and loss of appetite. Other reactions commonly observed in studies are corneal microdeposits (tiny deposits in the eye's surface) and elevated liver enzymes, which indicate changes in liver function.

Q: Does Angoron interact with common over-the-counter pain relievers?

A: Regulatory documents detail restrictions for certain drugs that are metabolized by specific liver enzymes, as well as other non-antiarrhythmic medicines that prolong the electrical recovery time of the heart. Due to Angoron's broad interaction profile, it is important to confirm the use of any over-the-counter pain relievers with a healthcare professional.

Q: Does Angoron have any known interactions with herbal supplements?

A: The official product label notes that Angoron is a potent inhibitor of various metabolic enzymes, which can increase the concentration of many co-administered substances, including supplements. Although specific herbal products may not be detailed in the official list, patients should ensure their healthcare provider is aware of all medicines, vitamins, and herbal supplements they are taking, given the potential for interactions.

Q: What if Angoron doesn't seem to be working for me?

A: The medicine's maximal therapeutic effect develops slowly due to its chemical properties, with full effects on heart rhythm often taking several months to achieve. Due to this slow accumulation, achieving the full therapeutic effect may take time. Any concerns regarding the drug’s perceived effect can be discussed with a healthcare professional.

Q: Is Angoron affected by cold or flu medicines?

A: Some cold and flu medicines are listed in regulatory drug interaction lists, such as those containing dextromethorphan (a common cough suppressant). Restrictions also exist for co-administration with other medicines that affect the heart's electrical recovery time. All co-administered medicines, including cold and flu preparations, should be disclosed to a healthcare professional for review.

Q: What should I do if I accidentally take too much Angoron?

A: Official patient information states that symptoms of a potential overdose may include a slow heart rate, lightheadedness, nausea, or blurred vision. Regulatory sources advise that emergency medical attention or contact with a Poison Help line may be necessary if an overdose is suspected.

Q: How should Angoron be stored at home?

A: The medicine must be stored at controlled room temperature, typically between 20^circ to 25 C (68^circ to 77 F). It should be kept in its original container, protected from light, moisture, and excessive heat, and securely stored out of the sight and reach of children.

Q: How quickly does Angoron usually start to work?

A: The onset of the drug's activity varies significantly by its route of administration. When given by intravenous infusion, antiarrhythmic activity can begin within a few hours. However, when taken orally, full effects often require an accumulation period of three to five months due to the medicine's slow absorption and distribution throughout the body.

Q: Is Angoron considered a 'strong' medicine?

A: The medicine is generally reserved for patients who have life-threatening heart rhythm problems and who have not responded to other antiarrhythmic agents. Regulatory documentation includes a serious Boxed Warning that details the potential for fatal toxicities, underscoring its significant risk profile and specialized use.

Q: Is it common to feel tired when first starting Angoron?

A: Official patient information mentions that feeling more tired than usual, known as fatigue or asthenia, is a possible symptom that may be associated with the drug's effects on the liver or thyroid. If persistent or severe tiredness is experienced, patients can discuss this with a healthcare provider.

Q: Can Angoron affect sleep?

A: Official patient resources list difficulty falling asleep or staying asleep, sometimes called insomnia or sleep disturbance, as a possible side effect of the medicine.

Q: Is Angoron safe for long-term use?

A: The regulatory safety profile highlights the potential for serious, long-term toxicities, such as pulmonary toxicity (lung damage), severe hepatotoxicity (liver damage), and thyroid problems, which are associated with extended exposure. For this reason, continuous, regular monitoring of organ function is mandatory for all patients on long-term therapy.

Q: Do older adults take a different dose of Angoron?

A: While regulatory dosing guidelines do not mandate a separate dose adjustment for older adults based on age alone, they do note that this population may be more susceptible to adverse reactions, such as a marked slowing of the heart rate. Treatment generally involves using the lowest effective dose to prevent the emergence of side effects.

Q: Is Angoron suitable for people with kidney problems?

A: Official regulatory guidelines state that a dose adjustment is typically not required for patients with kidney problems, as the medicine is primarily processed by the liver. However, patients with pre-existing conditions typically require close monitoring by a healthcare professional throughout treatment.

Q: Is it okay to stop taking Angoron suddenly?

A: Due to its use for life-threatening arrhythmias and its extremely long half-life, abruptly stopping the medicine may lead to the sudden return of the original heart rhythm problem. Any decision regarding discontinuing the medicine is generally required to be made under the direct supervision of a healthcare professional.

Q: Does Angoron change the way my heart feels?

A: Regulatory documents list side effects that directly affect heart function, including the onset or worsening of a heart rhythm problem (proarrhythmia) or a significantly slow heart rate (bradycardia). Feelings such as a pounding heart, skipping a beat, or unusual slowness are changes that can be immediately discussed with a healthcare professional.

Q: Why is Angoron sometimes given with another medicine?

A: The official label notes that Angoron is reserved for serious conditions and is often used when other antiarrhythmic medicines have failed. In cases where co-administration is necessary, regulatory information details mandatory restrictions, such as required dose reductions for drugs like Warfarin or Simvastatin, to manage potential interaction risks.

Q: Can Angoron cause dizziness or lightheadedness?

A: Official patient information explicitly lists feeling light-headed or faint as a potential symptom of a serious side effect, such as a very slow heart rate (bradycardia). If this occurs, regulatory patient information advises seeking immediate medical attention.

Q: How often do I need to see the doctor when I'm taking Angoron?

A: Official warnings state that regular monitoring is mandatory due to the risk of serious toxicity. This typically involves obtaining baseline tests before starting, and then periodic tests of the liver, thyroid, and lung function. The exact schedule is determined by the prescribing healthcare provider based on the patient's specific health status.

Q: Is there a generic version of Angoron available?

A: The active ingredient in Angoron is Amiodarone Hydrochloride. Regulatory agencies approve generic versions of medications that contain the same active ingredient, strength, and dosage form as the original brand-name product.

Q: Is there published research on Angoron's use in children?

A: The official regulatory label specifies that the safety and effectiveness of Angoron have not been established in the pediatric population.

Q: What kind of studies support the effectiveness of Angoron?

A: The medicine's effectiveness is supported by clinical studies, including randomized trials, that have examined its use in patients with life-threatening heart rhythm problems that were resistant to other treatments. These studies monitored the rate of heart rhythm episodes and functional outcomes in the patient populations studied.

Q: How is Angoron different from other drugs for the same condition?

A: Angoron is formally classified as a Class III Antiarrhythmic agent, which means its primary effect is to prolong the heart's electrical recovery time. Unlike many other agents, official documents note that it also exhibits characteristics similar to other classes, as it affects multiple channels (potassium, sodium, calcium) and blocks alpha- and beta-adrenergic receptors.

Q: Does Angoron affect blood sugar levels?

A: The official product label requires patients to inform their healthcare provider if they are taking medicines for diabetes. This is because Angoron and certain other medicines can interact, sometimes requiring a dose change or other form of monitoring.

Q: What does Angoron do to my blood vessels?

A: The drug's mechanism of action includes the blockade of alpha-receptors, which is described in official documents as contributing to peripheral vasodilation. This effect means that it can cause blood vessels located away from the heart to relax or widen, which in turn helps reduce cardiac strain.

Q: Will I need to take Angoron for the rest of my life?

A: The total duration of therapy is highly dependent on the type and severity of the heart rhythm problem being treated. For chronic, life-threatening conditions, long-term treatment is often necessary if the medicine is effective and well-tolerated. Any decision regarding the duration of treatment is made by a specialist.

Q: Can men experience sexual side effects from Angoron?

A: Official patient information resources list a decreased sex drive (libido) as a possible side effect of the medicine.

Q: Do I need to change my diet while taking Angoron?

A: Official regulatory documents specify that the co-administration of oral Angoron with grapefruit juice is restricted as it significantly increases the drug's absorption. Additionally, a high-fat meal is documented to dramatically increase the drug's oral absorption. Therefore, consistent timing in relation to meals is advised.

Q: What's the difference between the immediate-release and extended-release forms of Angoron?

A: Regulatory documents mention that the medication is supplied as oral tablets and as an injectable solution. Official product information does not establish a distinction between separate immediate-release and extended-release tablet formulations for this drug.

Q: Are the side effects worse when first starting Angoron?

A: Official safety information specifies that some effects, particularly gastrointestinal upset like nausea or vomiting, are often observed at the initiation of treatment. In contrast, serious toxicities, such as chronic liver disease or lung fibrosis, are typically associated with long-term exposure.

Q: Are there any tests required before starting Angoron?

A: Regulatory documents require that baseline tests be obtained before starting the medicine. These tests typically include monitoring of liver, thyroid, and lung function to establish a safety baseline.

Q: Is Angoron a diuretic ('water pill')?

A: Angoron is formally classified as a Class III Antiarrhythmic agent, and not a diuretic. However, medical literature has reported that the medicine can affect the body's water and electrolyte balance, sometimes requiring close monitoring of these levels.

How should Angoron be stored and disposed of?

Angoron (amiodarone) must be stored at controlled room temperature between 20 and 25 C (68 to 77 F). Protect the medication from light, moisture, and excessive heat. Do not refrigerate or freeze the product, as this can cause precipitation, and the solution must be clear for use. Keep the medication in its original container and out of the sight and reach of children.

For intravenous solutions diluted in dextrose 5%, the concentration must be at least 0.6 mg/ml to maintain stability, and the final dilution should preferably be administered using non-DEHP containing administration sets. Amiodarone solutions for infusion are typically stable for up to 24 hours at room temperature, depending on the concentration. Unused medication should not be disposed of via wastewater or household waste due to environmental concerns, as the product is toxic to aquatic life. Follow the specific instructions of your pharmacist or local waste management regulations for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Angoron found in:

A-Z Index: